WO2009148287A3 - Novel α-iso-cubebene compound extracted from schisandra chinensis and composition containing the compound as active ingredient for preventing and treating inflammatory diseases - Google Patents

Novel α-iso-cubebene compound extracted from schisandra chinensis and composition containing the compound as active ingredient for preventing and treating inflammatory diseases Download PDF

Info

Publication number
WO2009148287A3
WO2009148287A3 PCT/KR2009/003021 KR2009003021W WO2009148287A3 WO 2009148287 A3 WO2009148287 A3 WO 2009148287A3 KR 2009003021 W KR2009003021 W KR 2009003021W WO 2009148287 A3 WO2009148287 A3 WO 2009148287A3
Authority
WO
WIPO (PCT)
Prior art keywords
iso
cubebene
compound
expression
novel
Prior art date
Application number
PCT/KR2009/003021
Other languages
French (fr)
Korean (ko)
Other versions
WO2009148287A2 (en
Inventor
최영환
윤식
김치대
배외식
신동수
손병구
강점순
이유진
신우정
이희우
박지민
김지영
김지희
Original Assignee
부산대학교 산학협력단
동아대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 부산대학교 산학협력단, 동아대학교 산학협력단 filed Critical 부산대학교 산학협력단
Publication of WO2009148287A2 publication Critical patent/WO2009148287A2/en
Publication of WO2009148287A3 publication Critical patent/WO2009148287A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/79—Schisandraceae (Schisandra family)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
    • C07C13/28—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
    • C07C13/32—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings
    • C07C13/54—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with three condensed rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to a novel α-iso-cubebene compound which is extracted from Schisandra chinensis. As a result of using a TNF-α-stimulated HUVEC model, the extracted novel α-iso-cubebene compound has been proven to effectively suppress the generation of ROS, the expression of VCAM-1 and E-selectin, the activation of NF-B transcription factor and monocyte adhesion to endothelial cells. Especially, while the α-iso-cubebene suppresses TNF-α-induced expression of VCAM-1 and E-selectin which perform a pivotal role in in-vitro model of early atherogenesis, it does not change the expression of ICAM-1. In addition, during early atherogenesis, a cytokine such as TNF-α activates membrane-bound NADPH oxidase and stimulates intracellular ROS generation. Then, the cytokine activates an oxidation/reduction-sensitive transcription pathway such as NF-B and induces the expression of endothelial adhesion molecules. Since the α-iso-cubebene reduces the generation of ROS and suppresses the activation of oxidation/reduction-sensitive transcription factor NF-B, it suppresses TNF-α-stimulated VCAM-1 expression and monocyte adhesion to endothelial cells. Therefore, the α-iso-cubebene provides a composition for preventing and treating inflammation.
PCT/KR2009/003021 2008-06-05 2009-06-05 Novel α-iso-cubebene compound extracted from schisandra chinensis and composition containing the compound as active ingredient for preventing and treating inflammatory diseases WO2009148287A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0053169 2008-06-05
KR1020080053169A KR100991452B1 (en) 2008-06-05 2008-06-05 A compound for prevention and treatment for anti-inflammation using ??iso?cubebene compound extracted from Schisandra chinensis as effective component

Publications (2)

Publication Number Publication Date
WO2009148287A2 WO2009148287A2 (en) 2009-12-10
WO2009148287A3 true WO2009148287A3 (en) 2010-03-25

Family

ID=41398691

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/003021 WO2009148287A2 (en) 2008-06-05 2009-06-05 Novel α-iso-cubebene compound extracted from schisandra chinensis and composition containing the compound as active ingredient for preventing and treating inflammatory diseases

Country Status (2)

Country Link
KR (1) KR100991452B1 (en)
WO (1) WO2009148287A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101420007B1 (en) * 2012-08-16 2014-07-17 부산대학교 산학협력단 Composition for preventing or treating infectious and inflammatory disease comprising α-iso-cubebene as effective ingredient
WO2014027857A1 (en) * 2012-08-16 2014-02-20 부산대학교 산학협력단 Composition comprising alpha-iso-cubebene or alpha-iso-cubebenol as active ingredient for preventing or treating infectious or inflammatory diseases
KR101637433B1 (en) * 2014-05-12 2016-07-08 부산대학교 산학협력단 -- Composition for preventing or treating neurodegenerative disease containing -iso-cubebene
CN104644850A (en) * 2015-02-04 2015-05-27 新疆医科大学 Alpha-glycosidase inhibitory activity extract of fructus schizandrae as well as medical application and preparation methods of compositions thereof
KR102589451B1 (en) * 2021-06-24 2023-10-13 동의대학교 산학협력단 Anti-pollution composition containing schisandra chinensis extract

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19980083461A (en) * 1997-05-15 1998-12-05 박원훈 Use of a substance having an antagonistic activity against platelet activator receptor binding and a pharmaceutical composition containing the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19980083461A (en) * 1997-05-15 1998-12-05 박원훈 Use of a substance having an antagonistic activity against platelet activator receptor binding and a pharmaceutical composition containing the same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEN, H. ET AL.: "Changes in the Composition of Volatile Monoterpenes and Sesquiterpenes of Pinus amandi, P. tabulaeformis, and P. bungeana in Northwest China", CHEMISTRY OF NATURAL COMPOUNDS., vol. 42, no. 5, 2006, pages 534 - 538 *
HANNEN, P. ET AL.: "Platinum-and Gold-Catalyzed Rearrangement Reactions of Propargyl Acetates: Total Synthesis of (-)-alpha-Cubebene, (-)-cubebol, Sesquicarene and Related Terpenes", CHEMISTRY- A EUROPEAN JOURNAL., vol. 12, no. 11, 2006, pages 3006 - 3019 *
HYEON, GYU HWAN: "A Study on Determining Chemical Compositions of Schizandra chinensis", KOREAN JOURNAL OF PLANT RESOURCES., vol. 15, no. 1, 2002, pages 1 - 7 *
JANKOWSKI, C.K. ET AL.: "Unusual Isomerization of Cubebene", JOURNAL OF MEXICAN CHEMICAL SOCIETY., vol. 50, no. 3, 2006, pages 90 - 95 *

Also Published As

Publication number Publication date
KR20090126843A (en) 2009-12-09
WO2009148287A2 (en) 2009-12-10
KR100991452B1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
WO2009148287A3 (en) Novel α-iso-cubebene compound extracted from schisandra chinensis and composition containing the compound as active ingredient for preventing and treating inflammatory diseases
NZ597193A (en) Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
WO2009101503A3 (en) Use of natural active substances in cosmetic or therapeutic compositions
NZ717728A (en) Stable formulations of a hyaluronan-degrading enzyme
WO2007018588A8 (en) Stable pharmaceutical composition comprising linezolid form iv
WO2011027085A3 (en) Active principle from candida saitoana, and cosmetic use thereof for detoxifying skin cells
MX2020008890A (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy.
TW200800987A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
UA88780C2 (en) Alcohol metabolism moderating food composition
WO2007100901A3 (en) Epinephrine dosing regimens
GEP20146198B (en) Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
JP2013502227A5 (en)
AU311430S (en) Dispenser for personal care products
PE20090345A1 (en) BAKED COMPOSITION
ATE485046T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING CORDYCEPIN FOR THE TREATMENT AND PREVENTION OF OBESITY
MX2010000266A (en) A method for decreasing symptoms of alcohol consumption.
MX349406B (en) Personal care article for sequentially dispensing compositions with variable concentrations of hydrophobic benefit materials.
WO2008070859A3 (en) Treatment of skin conditions by dickkopf1 (dkk1)
TW200745132A (en) Novel, acyclically substituted furopyrimidine derivatives and use thereof
SG162766A1 (en) Benzooxazole-2-on derivatives as lipase and phospholipase inhibitors
TW200716581A (en) Benzothiazol-2-one derivatives as inhibitors of lipases and phospholipases
MX2009003060A (en) Emulsion.
MX2011006797A (en) Formulation for delivering lipid-lowering drugs by oral transmucosal administration.
UA108993C2 (en) MEDICINAL COMBINATION WITH THEOBROMINE AND ITS APPLICATION IN Cough
NZ599521A (en) Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09758540

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09758540

Country of ref document: EP

Kind code of ref document: A2